| Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans H McShane, AA Pathan, CR Sander, SM Keating, SC Gilbert, K Huygen, ... Nature medicine 10 (11), 1240-1244, 2004 | 759 | 2004 |
| Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans H McShane, AA Pathan, CR Sander, SM Keating, SC Gilbert, K Huygen, ... Nature medicine 10 (11), 1240-1244, 2004 | 759 | 2004 |
| Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases TJ Henrich, E Hanhauser, FM Marty, MN Sirignano, S Keating, TH Lee, ... Annals of internal medicine 161 (5), 319-327, 2014 | 455 | 2014 |
| Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara DP Webster, S Dunachie, JM Vuola, T Berthoud, S Keating, SM Laidlaw, ... Proceedings of the National Academy of Sciences 102 (13), 4836-4841, 2005 | 319 | 2005 |
| Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient SA Yukl, E Boritz, M Busch, C Bentsen, TW Chun, D Douek, E Eisele, ... PLoS pathogens 9 (5), e1003347, 2013 | 316 | 2013 |
| Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation TJ Henrich, Z Hu, JZ Li, G Sciaranghella, MP Busch, SM Keating, ... The Journal of infectious diseases 207 (11), 1694-1702, 2013 | 311 | 2013 |
| Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys NL Letvin, SS Rao, DC Montefiori, MS Seaman, Y Sun, SY Lim, WW Yeh, ... Science translational medicine 3 (81), 81ra36-81ra36, 2011 | 208 | 2011 |
| A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults VS Moorthy, EB Imoukhuede, P Milligan, K Bojang, S Keating, P Kaye, ... PLoS medicine 1 (2), e33, 2004 | 207 | 2004 |
| A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria … SJ Dunachie, M Walther, JE Epstein, S Keating, T Berthoud, L Andrews, ... Infection and immunity 74 (10), 5933-5942, 2006 | 196 | 2006 |
| Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers JM Vuola, S Keating, DP Webster, T Berthoud, S Dunachie, SC Gilbert, ... The Journal of Immunology 174 (1), 449-455, 2005 | 191 | 2005 |
| A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya P Bejon, J Mwacharo, O Kai, T Mwangi, P Milligan, S Todryk, S Keating, ... PLoS clinical trials 1 (6), e29, 2006 | 175 | 2006 |
| Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository R Kassanjee, CD Pilcher, SM Keating, SN Facente, E McKinney, MA Price, ... AIDS (London, England) 28 (16), 2439, 2014 | 160 | 2014 |
| Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against … SM Keating, P Bejon, T Berthoud, JM Vuola, S Todryk, DP Webster, ... The Journal of Immunology 175 (9), 5675-5680, 2005 | 158 | 2005 |
| The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of US women SM Keating, ET Golub, M Nowicki, M Young, K Anastos, H Crystal, ... AIDS (London, England) 25 (15), 1823, 2011 | 157 | 2011 |
| Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study T Kanias, MC Lanteri, GP Page, Y Guo, SM Endres, M Stone, S Keating, ... Blood advances 1 (15), 1132-1141, 2017 | 142 | 2017 |
| Synergistic DNA–MVA prime-boost vaccination regimes for malaria and tuberculosis SC Gilbert, VS Moorthy, L Andrews, AA Pathan, SJ McConkey, JM Vuola, ... Vaccine 24 (21), 4554-4561, 2006 | 142 | 2006 |
| Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men VS Moorthy, EB Imoukhuede, S Keating, M Pinder, D Webster, ... The Journal of infectious diseases 189 (12), 2213-2219, 2004 | 136 | 2004 |
| Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys J Liu, BF Keele, H Li, S Keating, PJ Norris, A Carville, KG Mansfield, ... Journal of virology 84 (19), 10406-10412, 2010 | 124 | 2010 |
| A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS, S/AS02A and MVA-CS SJ Dunachie, M Walther, JM Vuola, DP Webster, SM Keating, T Berthoud, ... Vaccine 24 (15), 2850-2859, 2006 | 118 | 2006 |
| The induction and persistence of T cell IFN-γ responses after vaccination or natural exposure is suppressed by Plasmodium falciparum P Bejon, J Mwacharo, O Kai, S Todryk, S Keating, B Lowe, T Lang, ... The Journal of Immunology 179 (6), 4193-4201, 2007 | 107 | 2007 |
Michael BuschDirector, Blood Systems Research Institute; Professor of Lab Med, UCSFAdresse e-mail validée de bloodsystems.org
